Expression of the tyrosine kinase c‐kit is an independent prognostic factor in patients with small cell lung cancer

In a retrospective analysis of 203 patients with small cell lung cancer (SCLC), we examined the prognostic value of c‐kit expression on survival. Expression of c‐kit was examined immunohistochemically in formalin‐fixed, paraffin‐embedded tissue sections. c‐kit was observed in 87.7% of SCLC tumors. Using the Kaplan‐Meier model, we found that lack of c‐kit expression was associated with significantly shorter survival time compared to the presence of c‐kit expression (mean survival 151 ± 27 vs. 358 ± 49 days, p = 0.0084). Moreover, the proportion of c‐kit+ cells within the tumor was also related to survival time. Patients with tumors in which >75% of cells stained positive for c‐kit had a mean overall survival time of 424 (±72) compared to 295 (±67) days for patients with 25–75% c‐kit+ tumor cells. Patients with tumors containing <25% c‐kit+ cells had the worst survival, with 164 (±24) days (p = 0.0033). Further parameters associated with short survival times were low performance status, elevated levels of lactate dehydrogenase and higher stage according to the TNM classification. Multivariate analysis using the Cox regression model showed that the proportion of c‐kit+ cells within the tumor specimen was one of 3 independent prognostic parameters (p = 0.004) for overall survival next to TNM classification (p = 0.001) and performance status (p < 0.001). © 2004 Wiley‐Liss, Inc.

[1]  M. Tsao,et al.  Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  A. Potti,et al.  CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  J. Verweij,et al.  Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens. , 2003, European journal of cancer.

[4]  F. Oesch,et al.  Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  S. Alkan,et al.  Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis. , 2002, Human pathology.

[6]  G. Demetri,et al.  Management of malignant gastrointestinal stromal tumours. , 2002, The Lancet. Oncology.

[7]  J. Fletcher,et al.  Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. , 2002, Human pathology.

[8]  S. Honsawek,et al.  The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  R. Salgia,et al.  Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571 , 2000, Oncogene.

[10]  C. Mountain,et al.  The international system for staging lung cancer. , 2000, Seminars in surgical oncology.

[11]  J. Lasota,et al.  Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. , 1999, The American journal of pathology.

[12]  M. Yamakido,et al.  Specific Growth Inhibition of Small‐cell Lung Cancer Cells by Adenovirus Vector Expressing Antisense c‐kit Transcripts , 1996, Japanese journal of cancer research : Gann.

[13]  G. Krystal,et al.  Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. , 1996, Cancer research.

[14]  E. Thiel,et al.  Recombinant human stem cell factor does exert minor stimulation of growth in small cell lung cancer and melanoma cell lines. , 1995, European journal of cancer.

[15]  R. Ueda,et al.  Ectopic expression of c‐kit in small‐cell lung cancer , 1994, International journal of cancer. Supplement = Journal international du cancer. Supplement.

[16]  T. Tsukamoto,et al.  Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the c-kit protooncogene. , 1993, Cancer research.

[17]  T. Nakamura,et al.  Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. , 1993, British Journal of Cancer.

[18]  A. Ullrich,et al.  Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. , 1992, Cancer research.

[19]  T Takahashi,et al.  Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. , 1991, Oncogene.

[20]  R. Ueda,et al.  Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. , 1991, Cancer research.